Clinical trials: Chronic Obstructive Pulmonary Diseases
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238158
- Testing
- Atrovent® inhalets
- Volunteers
- 595 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02294734
- Testing
- GSK2269557
- Where
- 17 sites in Belgium, Denmark and 3 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 microgram tiotropium bromide solution for inhalation, delivered by the Respimat® inhaler, once daily for four weeks in…
- Trial name
- NCT00720499
- Testing
- BI 1744 CL plus tiotropium bromide, Respimat® Inhaler
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 141 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Phase I Study of GW642444M in Healthy Japanese Male Subjects
This is a randomized, double blind, placebo controlled, parallel-group, 7 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose of GW642444M from a novel dry powder…
- Trial name
- NCT00964249
- Testing
- GW642444
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma, COPD
Assess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis
Current diagnostic methods for asthma and chronic obstructive pulmonary disease mostly depend on pulmonary function tests, especially spirometry.
- Trial name
- Care4All (NCT07245576)
- Where
- 12 sites in Argentina, Egypt and 5 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Chronic Hepatitis B
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)
This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.
- Trial name
- NCT00140725
- Testing
- Lamivudine plus Polyethylene glyco-interferon alfa-2b, Lamivudine
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
The objective of this trial was to assess the efficacy and safety of aerosolized liposomal cyclosporine A (L-CsA) as add-on therapy to standard of care (SoC) as compared to SoC alone in double lung transplant (DLT) recipients…
- Conditions
- Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications
- Trial name
- BOSTON-2 (NCT03656926)
- Testing
- Liposomal Cyclosporine A, Standard of Care
- Where
- 40 sites in United States, Austria and 7 more
- Volunteers
- 169 people
- Sponsor
- Zambon SpA
Chronic Wounds
P.E.M.F. Therapy of Chronic Wounds
To measure the effectiveness of pulsed electromagnetic fields (PEMF) as an adjunct wound care therapy.
- Trial name
- NCT05493943
- Testing
- Pulsed ElectroMagnetic Field (PEMF) therapy, Pulsed ElectroMagnetic (PEMF) therapy
- Volunteers
- 120 people
- Sponsor
- PEMF Systems, Inc.
COPD
Study in Patients With COPD
The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.
- Trial name
- NCT00215449
- Testing
- Formoterol Fumarate
- Where
- 68 sites in United States
- Volunteers
- 690 people
- Sponsor
- Dey
Chronic Obstructive Pulmonary Disease, Asthma
Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients
The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide using a Gamma-scintigraphic technique after inhalation of a single…
- Trial name
- NCT02975843
- Testing
- Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients
The goal of this observational study is to measure improvement in health related quality of life in moderate to severe COPD patients treated with Trimbow inhalation powder.
- Trial name
- RESPONSE (NCT05743608)
- Where
- 39 sites in Hungary
- Volunteers
- 1,336 people
- Sponsor
- Chiesi Hungary Ltd.
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with…
- Trial name
- NCT01323634
- Testing
- Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
- Where
- 50 sites in United States, Czechia and 4 more
- Volunteers
- 519 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)
Chronic obstructive pulmonary disease (COPD) is a progressive and largely irreversible lung disease characterized by chronic bronchitis and/or emphysema, resulting in breathlessness, cough and sputum.
- Trial name
- DACOTA (NCT01285167)
- Testing
- Daxas
- Where
- 605 sites in Germany
- Volunteers
- 3,645 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will evaluate the pharmacokinetics, pharmacodynamics and safety of multiple doses of the NVA237 in mild and moderate COPD patients .
- Trial name
- NCT00545311
- Testing
- NVA237
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 40 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
- Trial name
- NCT00419744
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
An Investigation of the Past 10 Yrs Health Care for Primary Care Patients With Chronic Obstructive Pulmonary Disease
The aim of this study is to describe COPD health care and to assess demographics, concurrent diseases and mortality and the use of pharmaceuticals for a chronic obstructive pulmonary disease (COPD) population in real life in…
- Trial name
- PATHOS (NCT01146392)
- Where
- Sweden
- Volunteers
- 27,394 people
- Sponsor
- AstraZeneca
Chronic Hepatitis B
Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects
This study will assess the efficacy of ABF656 in chronic hepatitis B characterized by HBeAg positivity. The study is designed to establish a dose response and safety relationship sufficient to allow the subsequent design and…
- Trial name
- NCT00964665
- Testing
- albinterferon alfa-2b, Pegasys®
- Where
- 12 sites in China, Hong Kong and 3 more
- Volunteers
- 141 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19, Chronic Bronchitis
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD
Evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated COVID-19 vaccine .
- Conditions
- COVID-19, Chronic Bronchitis, COPD
- Trial name
- NCT05104216
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
COPD
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, parallel arm study. The study population will consist of subjects, 35 to 75 years of age, with a diagnosis of moderate to severe COPD per Global Initiative for Chronic…
- Trial name
- GOLDEN-2 (NCT01706536)
- Testing
- EP-101 12.5 mcg, EP-101 25 mcg, EP-101 50 mcg
- Where
- 26 sites in United States
- Volunteers
- 275 people
- Sponsor
- Sunovion Respiratory Development Inc.
Pulmonary Disease, Chronic Obstructive
Research to Evaluate a Possible Relation Between Values Obtained After Processing CT Images, Lung Function Tests and the Experience of the Patient During an Exacerbation in COPD Patients.
In this study the consequences of exacerbations will be visualized by high resolution computed tomography (HRCT) scan at functional residual capacity (FRC) and total lung capacity (TLC) as taken during an episode of exacerbation…
- Trial name
- NCT01684384
- Testing
- Functional Respiratory Imaging
- Where
- 4 sites in Belgium, Italy and 1 more
- Volunteers
- 53 people
- Sponsor
- FLUIDDA nv
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.